首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy
【24h】

Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy

机译:加拿大癌症试验组(CCTG)IND211:在接受标准救助治疗的先前治疗的晚期或转移性非小细胞肺癌患者中Pelareorep(Reolysin)的随机试验

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Objectives: Pelareorep (reolysin), a Dearing strain of reovirus serotype 3, has demonstrated oncolytic activity as single agent and synergy with chemotherapy. We evaluated pelareorep, combined with standard second-line chemotherapy in patients with non-small cell lung cancer (NSCLC).
机译:目的:Pelareorep(Reolysin)是一种贪婪的reovirus血清型3株,已作为单一剂和化疗协同作用。 我们评估了Pelareorep,结合了非小细胞肺癌(NSCLC)患者的标准二线化疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号